Author:
Kahlon Navkirat,Doddi Sishir,Ning Ying,Akpunonu Basil,Murphy Julie
Reference11 articles.
1. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis;Wang X;J Clin Pharmacol,2016
2. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban;Chang M;J Clin Pharmacol,2016
3. International normalized ratio is significantly elevated with rivaroxaban and apixaban drug therapies: a retrospective study;Ofek F;Clin Ther,2017
4. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects;Frost C;Br J Clin Pharmacol,2013
5. Evaluation of the effect of apixaban on INR in the inpatient population;Kovacevic MP;J Cardiovasc Pharmacol Ther,2019
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献